Monitor upcoming MICVO data readouts (mid-2026 and 2H26) for potential catalysts; limited cash runway suggests financing risk if trials delay.
PYXS drugs
PYXS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $2.21entry
- T+1 · 6mo ago +3.17%α +4.39% · $2.28
- T+5 · 6mo ago −12.22%α −11.50% · $1.94
- T+20 · 5mo ago −20.36%α −19.50% · $1.76
- T+60 · 3mo ago +73.30%α +69.71% · $3.83
Price Chart
How similar events traded
Executive Summary
Pyxis Oncology reported Q1 2026 EPS of -$0.37, missing consensus of -$0.35 by 5.7%. The clinical-stage biotech has $42.5M cash runway into Q4 2026 and reiterated MICVO Phase 1 monotherapy data for mid-2026 and combination data for 2H26. The modest earnings miss is typical for pre-revenue companies and overshadowed by pipeline milestones.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.37 vs consensus -$0.35 (5.7% miss)
- Cash and investments $42.5M, runway into Q4 2026
- MICVO Phase 1 monotherapy update expected mid-2026, combination data 2H26
- No revenue (clinical-stage biotech)
Financial Impact
Net loss of $23.3M in Q1 2026, up from $21.2M in Q1 2025; cash burn $42.5M remaining
Risk Factors
- Cash runway only into Q4 2026, possible dilution if milestones slip
- Clinical trial failure risk for MICVO
- Pre-revenue stage with no near-term revenue prospects
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294764 |
Track record
25 reports on PYXS
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
- Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
- Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
- Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
- Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
- Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
- Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers